Neuropeptide Y (NPY) has been suggested as an important regulator of CBF, However, except for the presence of Yl receptors in large cerebral arteries, little is known about its possible sites of action on brain vessels, In this study, we sought to identify the NPY receptors present in the human cerebrovascular bed, Specific Y I receptor binding sites, local ized on the smooth muscle of human pial vessels and potently competed by NPY, polypeptide YY (PYY), and the selective Yl receptor antagonist BIBP 3226, were identified by quanti tative radioautography of the Y 1 radioligand C 25I]_[Leu31, pro34]_pyy, In contrast, no specific binding of the Y2_(C25I]_ PYY 3 -3 6 ) and Y4/Y5-C25I-human pancreatic polypeptide [hPP]) radioligands could be detected, By in situ hybridization, expression of Yl receptor mRNA was restricted to the smooth muscle layer of pial vessels, whereas no specific signals were detected for either Y2, Y4, or Y5 receptors, Similarly, using reverse transcriptase-polymerase chain reaction (RT-PCR),
projection fibers have been shown to associate with local microvessels and their perivascular astrocytes, and could therefore affect brain perfusion (see Abounader and Hamel. 1997a . for additional references). In fact, intra carotid or local intraparenchymal (Suzuki et aI., ] 989; Tuor et aI.. 1990) injection of NPY in the rat is known to result in a strong reduction in CBF in the ipsilateral hemisphere or locally in the ipsilateral striatum and ad jacent areas. These contractile in vivo effects are fully compatible with the ability of NPY to induce long lasting and sustained vasoconstriction of isolated brain extraparenchymal (Edvinsson et aI., 1987) and intrapa renchymal (Dacey et aI., 1988) blood vessels. However, a transient NPY -mediated cerebral vasodilation, presum ably mediated by nitric oxide, also has been reported after intracarotid injection of NPY in the cat (Kobari et a1.. ] 993).
In large cerebral arteries of various species including man, the NPY-induced contractile effect has been shown to be mediated by the NPY -Y 1 receptor subtype (Abou nader et aI., 1995; Nilsson et aI., 1996) . In peripheral vascular beds from some species, however, pharmaco logic studies suggest that Y1 and possibly Y2 receptors are involved in this contractile response (Grundemar et aI., 1992; Tessel et aI., 1993) . Alternatively, Y2 receptors could mediate the vasodilatory effects of NPY either directly (Neild and Lewis, 1995) or indirectly through presynaptic regulation (Hashim and Tadepalli, J 995) . In the cerebral microvascular bed, little is known on the types of NPY receptors present on these nonneuronal cells. Such information is crucial to a better understand ing of the role of NPY in cerebrovascular physiology and, possibly, pathophysiology, as suggested by the marked increases in NPY mRNA expression and immu noreactivity after focal ischemia in rats (Cheung et aI., 1995) .
Six different NPY receptors (Yl, Y2, Y3, Y4, Y5, and Y6) have been described with different affinities for NPY, polypeptide YY (PYY), the pancreatic polypep tides CPP) and their derivatives (Wahlestedt et aI., 1986; Dumont et aI., 1995; Gerald et aI., 1996; Weinberg et aI., 1996) . With the exception of the Y3 SUbtype, all recep tors have been cloned (Herzog et aI., 1992; Larhammar et aI., 1992; Gerald et aI., 1996; Rose et aI., 1995; Bard et aI., 1995; Weinberg et aI., 1996) . In cerebral arteries, a Y1 receptor has been unequivocally identified pharma cologically (Abounader et al., 1995) and by expression of its mRNA (Nilsson et aI., 1996; Abounader and Hamel, 1997 b) ; message for the Y 4 receptor type has been detected only in human coronary artery (Bard et aI., 1995) .
In the current study, we used pharmacologic and mo lecular approaches to investigate the expression of NPY YI, NPY-Y2, NPY-Y4, and NPY-Y5 receptor messages and proteins in human pial vessels, intracortical blood vessels, and cerebromicrovascular and astroglial cells in culture. The results indicate that only the Yl receptor is consistently expressed in human cerebrovascular tissues, and that it is exclusively localized to smooth muscle cells where NPY application is coupled to inhibition of ade nylyl cyclase activity. Furthermore, they show the ex pression of Y1, Y2, and Y4 receptor types in human brain astroglial cells in culture. Part of these data has appeared in an abstract form (Abounader and Hamel, 1997b) .
METHODS

Human cerebrovascnlar tissues
Human tissues were obtained with approval from the Insti tutional Research Ethics Committee from male and female in dividuals who either died from diseases not related to the CNS (n = 9, postmortem delay 2 to 18 hours; Brain Bank from the Douglas Hospital Research Centre, Verdun, QC, Canada) or were undergoing temporal lobe surgery at the Montreal Neu-J Cereb Blood Flow Metah. Vol. 19, No.2, 1999 rological Institute for the treatment of epilepsy (n = 6). Pial vessels (from postmortem brains) were dissected out and cleaned, and underlying cortical brain tissue then was imme diately used for isolation of intraparenchymal microvessels (MV) and capillaries (CAP), as previously described (Linville and Hamel, 1995) . Pial vessels, MV, and CAP were either frozen in cold isopentane (-45°C; for radioautography and in situ hybridization) or in liquid nitrogen (for reverse transcrip tase-polymerase chain reaction [RT-PCR] ) and stored at -80°C until use.
Cell cultures
Human pial vessel endothelial cells were obtained by enzy matic stripping of pial arteries. After removing intraluminal debris with Ca2+-and Mg2+-free phosphate-buffered saline, 0.5% trypsin was injected into the lumen and kept in place for 5 minutes. The intraluminal content then was recovered into a small volume of endothelial cell culturing media (65% medium M 199 containing Earle's salts, 25 mmollL Hepes, 4,35 gIL sodium bicarbonate, and 3 mmollL L-glutamate, 10% fetal calf serum, 5% human serum, 20% murine melanoma cell conditioned media, 5 j.1g/mL insulin, 5 j.1g/mL transferrin and 5 ng/mL selenium, 10 j.1g/mL endothelial cell growth supple ment, and 100 j.1m/mL heparin) (Stanimirovic et aI., 1996) , and seeded onto 0.5% gelatin-coated tissue culture dishes. Cultures reached confluence after 2 weeks, displayed cobblestone mor phologic features, and contained more than 95% of factor VIII positive cells. Endothelial cells generated from two separate segments of pial vessels removed from one brain autopsy were used in this study.
Cultures of human cerebromicrovascular smooth muscle (SMC) and endothelial (END) cells were generated from sur gically removed brain tissue. The SMC cultures were derived from large intraparenchymal microvessels isolated by a sequen tial filtration of brain homogenate through 350-and 112-j.1m mesh screens. These resistance microvessels then were dis lodged from the mesh screens with cold medium M199, washed, dissociated with the type IV collagenase (1 mg/mL, 15 minutes), and seeded onto 0.5% gelatin-coated culture plates in the medium containing 65% medium M199, 10% fetal calf serum, 5% human serum, 5 j.1g/mL insulin, 5 j.1g/mL transfer rin, and 5 ng/mL selenium. After 4 to 5 weeks in culture, more than 85% of cells stained positively for the smooth muscle a-actin, whereas about 10% of cells demonstrated endothelial cell morphologic features and incorporated acetylated low den sity lipoprotein. Six SMC-enriched cultures derived from the microvessels harvested from the 350 j.1m (n = 4) and 112 j.1m (n = 2) mesh screens were used in the current study.
To initiate brain microvessel and capillary END cell cultures, brain homogenate depleted of large microvessels was centri fuged in 20% dextran (3000 g, 15 minutes), the pellet was resuspended in cold medium M 199, and microvessels collected on a 20-j.1m mesh. The vessels were dissociated with the type IV collagenase, seeded, and maintained at 37°C in endothelial cell culturing media described earlier. The END cells were purified from the culture 4 to 5 days after seeding using cloning rings (BELLCO Glass, Inc., Vineland, NJ, U.S.A.). More than 95% of cells derived by these procedures were immunocyto chemically positive for factor VIII-related antigen and ex pressed high levels of the cerebral endothelium-specific en zymes, ')'-glutamyl-transpeptidase and alkaline phosphatase (Stanimirovic et aI., 1996) . The morphologic, phenotypic, bio chemical, and functional characteristics of END cultures used in this study have been described in detail previously (Stan imirovic et a!., 1996) . The END cells (passages 3 to 7) from six different human brain biopsy specimens were used in this study.
Cultures of fetal (10 to 18 weeks of gestation) human brain astrocytes (AST) (n = 5) were provided by Drs. J. Antel and W. Yong (Montreal Neurological Institute, Montreal, QC, Canada) and prepared using established procedures (Yong et a!., 1992) . Brains were trypsinized (0.25%), homogenized, and filtered through a 130-f.1m mesh. Cell pellets were resuspended in a 95% Dulbecco's modified Eagle's medium (4500 gIL glu cose) containing 5% fetal bovine serum, and plated onto poly L-lysine--coated tissue culture dishes. Contaminating neurons disappeared after trypsinization and passaging. More than 95% of the cells in cultures used in this study (passages 2 to 5) were immunopositive for the glial fibrillary acidic protein (Y ong et a!., 1992).
Radioautography and in situ hybridization
Pial vessel cross-sections (20-f.1m thick) were cut on a cryo stat, mounted either on gelatin-coated slides, and stored at -90°C until use (radioautography) or on clean RNAase-free slides (Superfrost plus, Fisherbrand) and stored at -20°C for no more than 24 hours (in situ hybridization).
Radioautography. For radioligand binding studies, sections were preincubated (60 minutes, room temperature) in 1.2 mmollL Krebs-Ringer phosphate buffer (containing 0. 12 mollL NaCI, 4.7 mmollL KCl, 2.5 mmollL CaCI 2 , 1.2 mmollL After rinsing and dehydration, sections were directly apposed to Kodak XAR films and exposed for 2 to 15 days (4°C). Film radioautograms were used for quantitative densitometry per formed on a microcomputer-based image analysis system (The Image Calculator, Soquelec, Ltd., Montreal, QC, Canada). The pICso values (mean ± SD, n = 2 or 3 different experiments) for each agonist or antagonist were determined from the competi tion curves, and the total binding was set at 100%.
In situ hybridization. Pial vessel sections were thawed, fixed (Larhammar et al., 1992; Rose et aI., 1995; Bard et a!., 1995; Gerald et aI., 1996) . They were syn thesized in an Applied Biosystems synthesizer and purified using an OPC column (Applied Biosystems). Some oligo nucleotide primers were flanked with the restriction enzyme EcoRl (GAATTC) and BamHI (GGATCC) sequences. The primers were as follows: YI (Genbank accession #M88461), Y I-Forward: 5' -TCAGGATCCAACATCCTGATTGT GAAAC-3' and YI-Reverse: 5'-TACTGCAGCACCAAGA GGAG-3', yielding a PCR product of 43 5 base pairs; Y2: (Genbank accession #36269), Y2-Forward: 5'-TGAATT CATATTGGCCTACTGCTCC-3' and Y2-Reverse: 5' CTGGATCCTGCCATAGATGCTCTTCTCC-3' , PCR prod uct of 492 base pairs; Y4 (Genbank accession #U3523 2), Y4-Forward: 5' -TGAATTCTTCATCGTCACTTCCT ACAGC-3' and Y 4-Reverse: CTGGATCCTAACAGACCAGGAT GAAGCC-3' with PCR product of 575 base pairs; and Y5 (Genbank accession #U5607 9). Y5-Forward: 5' TGAATTCGACACTAGGTTTTGCCATCTG-3' and Y5-Reverse: 5'-CTGGATCCGGACCCCTGGTATGAACTTA-3', yielding a PCR product of 510 base pairs. The PCR products were size-fractionated by electrophoresis on a 1.5% Trisl borate/ethylenediamine-tetraacetic acid agarose gel containing ethidium bromide, their size confirmed, and then photographed under ultraviolet light. Representative PCR fragments for the Yl (SMC), Y2, and Y4 (AST) receptors were used for sequenc ing analysis using direct automated fluorescent sequencing (W.N. Keck Foundation Biotechnology Resource Laboratory, Yale University, New Haven, CT, U.S.A.).
Second messenger assays
The presence of functional NPY receptor proteins in micro vascular cells was evaluated by measuring the ability of NPY to affect cAMP production in cultured human brain SMC (n = 4) and END (n = 3) cells, a pathway previously correlated to the vasoconstrictor activity of NPY (Lundberg et aI., 1988) . For comparison, one preparation of endothelial cells derived from human pial vessels also was used. Cells grown to confl uence in 24-well tissue culture plates were incubated (15 minutes, 37°C) in phosphate-buffered saline containing 0.2% bovine serum albumin and 1 mmollL 3-isobutyl-l-methyl-xanthine with NPY (0.1 andlor I f,LmollL) either alone or in the presence of 1 f,LmollL forskolin. The reaction was stopped the double extrac tion with 65% (v/v) ice-cold ethanol. The extracts were com bined, dried (vacuum oven at 80°C) and dissolved in 200 f,LL of the assay buffer for measurement of cAMP levels with a com mercial enzyme immunoassay kit (Biotrak, Amersham). The cell pellets were solubilized in 0. 1 N NaOH and used for pro tein measurement by the method of Lowry and coworkers (1951) . Statistical differences (P "" 0.05) were evaluated by Student's t test.
RESULTS
Localization of neuropeptide Y receptor mRNA in human pial vessels
As shown in Fig. 1 , sections incubated with a selective YI receptor e S S]-labeled cRNA antisense probe exhib ited a high density of silver grains, located primarily if not exclusively on the smooth muscle layer of human pial vessels (Fig. lA) . Although silver grains could ac cumulate at the border of the elastic lamina (Fig. lA,  arrow) , endothelial cells remain unlabeled. No specific signal was observed in sections incubated with either the YI sense riboprobe (Fig. I B) Figs. 2A and B) .
In contrast, incubation with the Y2_( '2S I-PYY 3 -3 6) and Y 41Y 5-( 12S 1 -hPP) receptor ligands yielded no specific binding in any of the cellular compartments of the human pial vessels, as shown by the similar distribution and low density of silver grains in sections incubated under both total and nonspecific binding conditions (Figs. 2C through F). Quantitative densitometry of film radio auto grams from human pial vessel sections incubated with the Yl radioligand 125 1 _[Leu 31 , pro 34 ]_PYY showed competition of the bound ligand from the muscle layer by increasing concentrations of unlabeled NPY, PYY, and the selective YI receptor antagonist BIEP 3226 (Fig. 3A) . Their re spective plCso values were of 7.86 ± 0.06, 7.43 ± 0.04, and 8.42 ± 0.21 (mean ± SD). Nonspecific binding (evaluated in the presence of 10-6 molfL of NPY, PYY, or BIEP, respectively) corresponded to about 25% to 35% of total binding (Fig. 3A) . The YI radioligand 3 H_ BIEP 3226 was competed from the pial vessel sections in a concentration-dependent manner by NPY with a cal culated plCso value of 8.01 ± 0.01 (mean ± SD) (Fig,  3B) . In contrast, film densitometry showed no significant difference in the density of binding sites between sec tions incubated with the radioligand alone or in the pres ence of various concentrations (10-9 to 10-6 molfL) of either NPY, [Leu 31 _Pro 34 ]_NPY, or NPY 13 -3 6 for Y2-( 125 I-PYY 3 _ 3 6) sites, or hPP (10-7 to 10-10 molfL) in the case of Y41Y5-( 12S I-hPP) binding sites.
Neuropeptide Y receptors expression in cerebrovascular tissues and microvascular and astroglial cells
In agreement with radioautographic and in situ hybrid ization experiments, specific PCR products of the ex pected size (435 bp) for the Yl receptor were detected in most (67% to 100%) human pial vessels, isolated MV, and CAP, as well as in most SMC and AST cell cultures (Fig. 4, top panel) . However, no amplification of Y1 receptor message could be evidenced in endothelial cells derived from pial vessels or in any of the cerebromicro vascular END cell cultures tested (Fig. 4, top panel) . Message for the Y2 receptor was detected in a few (ap proximately 20%) of vascular preparations and a single culture of microvascular endothelial cells. Messages for the Y4 and Y5 receptors could not be detected in any of the vascular tissues, END, or SMC cultures (Fig. 4) . c E However, PCR products of the expected size for the Y2 (491 bp) and Y4 (578 bp) receptors were detected by gel electrophoresis in most (80% and 67%, respectively) of AST cells in culture (Fig. 4, middle and bottom panels) . Sequence analysis of the selected PCR products matched the published sequences for their respective cloned hu man Yl (99.8%), Y2 (99%), and Y4 (99.5%) NPY re ceptors.
Functional neuropeptide Y receptors in microvascular cell cultures
As shown in Fig. 5 , functional NPY receptor proteins were detected in the muscular compartment of cerebral microvessels. The basal release of cAMP was slightly inhibited by NPY in SMC (about 30%, not significant) but not in END cells. Forskolin (l f-LmoIlL) resulted in a 10-to 20-fold increase in cAMP production in these cultures (Fig. 5) . The NPY (0.1 and 1 f-LmoIlL) signifi-
cantly (P < 0.05) inhibited the forskolin-stimulated cAMP production in SMC (40% and 51 %, respectively), whereas a 1-f-LmoI/L NPY concentration had no effect on the evoked cAMP production in microvascular END cell cultures (Fig. 5 ) or in endothelial cells derived from hu man pial vessels (data not shown).
DISCUSSION
This study provides the first comprehensive analysis of NPY receptors message and protein distribution, as well as cellular localization in human cerebral blood ves sels. The results obtained by both pharmacologic and molecular approaches suggest that the Yl receptor sub type is the only receptor, of the known and cloned human NPY receptors, to be significantly expressed in human brain vessels, irrespective of their extraparenchymal or intraparenchymal location. These NPY receptors are ex clusively located on the smooth muscle cell layer not 
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only of pial arteries, but also of intracortical microves sels, where they were shown to inhibit adenylyl cyclase activity. Moreover, the results show that brain astrocytes express multiple NPY receptor subtypes, identified as YI, Y2, and Y4 by RT-PCR. Taken together, these data indicate that NPY has the ability to influence nonneuro nal cells within the human brain by stimulating vascular Y I and heterogeneous astroglial NPY receptors and, as such, could participate in the regulation of brain perfu sion and metabolic or ionic homeostasis. The identification of Yl receptors in human pial ves sels by in situ hybridization and radioautography agrees with previous pharmacologic and RT-PCR studies (Abounader et al., 1995; Nilsson et aI., 1996) . However, the results further indicate that the Yl receptor is the only NPY receptor associated with human cerebral arteries, and that it has an exclusive muscular localization. This localization concurs with a recent immunocytochemical study of cerebrovascular YI receptors in the rat (Bao et aI., 1997) . The Yl nature of the human cerebrovascular NPY receptor is pharmacologically supported by the po tency of NPY, PYY, and the Yl receptor antagonist BIEP 3226 (respective pIC so values of 7. 86, 7.43, and 8.42) in competing for 125 I_[Leu 31 _Pro 34 ]_PYY_labeled specific smooth muscle binding sites. These compare well with the affinities reported for these compounds at the cerebrovascular Yl receptor mediating contraction of human cerebral arteries (Abounader and Hamel, 1995; Nilsson et aI., 1996) . In addition to vasoconstriction, other roles for cerebrovascular smooth muscle Y 1 recep tors could be considered, such as mediation of mitogen esis, as reported in peripheral vascular smooth muscle cells (Zukowska-Grojec et aI., 1993) . The results suggest that human cerebral arteries differ from some peripheral (femoral and intestinal) vascular beds in animal species in which both muscular Y 1 and Y2 receptors have been implicated in the control of ar terial or arteriolar vascular tone (Tessel et aI., 1993; Neild and Lewis, 1995) . Indeed, no evidence was ob tained from the current molecular or anatomical studies for the presence of smooth muscle Y2 receptors in hu man brain vessels. Whereas the Y3 receptor also has been pharmacologically excluded as the mediator of the NPY-induced human cerebral vasoconstriction (Abou nader and Hamel, 1995) , additional work is required to verify its status at the cerebrovascular level when the human clone becomes available. Based on the current molecular and radioligand binding data, it is unlikely that Y4 and Y5 receptors exist in the human cerebrovascular bed in any significant amount.
A novel finding from the current study is that of a selective expression of Y I receptor mRNA in the human brain microvascular bed, more specifically, at the level of the smooth muscle cells where the presence of func tional receptor proteins was confirmed by the ' ability of NPY to inhibit cAMP production. Such association of microvascular Y 1 receptors with the smooth muscle cell layer of human intracortical microvessels is fully com patible with the recent immnocytochemical demonstra tion of Yl receptor in rat brain microarterioles (Bao et aI., 1997) and with previous reports in rodents suggesting that Yl receptors mediate the endothelium-independent NPY vasoconstriction in the microcirculation, albeit of peripheral origin (Kim et aI., 1994) . The presence of smooth muscle Yl receptors in human intracortical mi crovessels strongly suggests that perivascular NPY nerve terminals (Abounader and Hamel, 1997a) could induce local cerebral vasoconstriction, a hypothesis supported by previous observations in the rat of a local decrease in CBF after intraparenchymal application of NPY (Tuor et aI., 1990) and of an NPY -induced contractile response in isolated intracortical arterioles (Dacey et aI., 1988) . The ability of NPY to inhibit the forskolin-stimulated in crease in cAMP levels in human cerebromicrovascular However, NPY (1 �moIlL) significantly inhibited (51%, P < 0.05) the forskolin-induced cAMP production in SMC while having no effect in END cells. Bars = SO; .p < 0.05.
SMC cells, a signaling pathway associated with a direct vasocontractile response to NPY (Lundberg et aI., 1988; Larhammar et aI., 1992) , further supports such a role for NPY at the microvascular level. The failure to detect NPY receptors in a significant proportion of endothelial cells further suggests that mus cular YI receptors are the primary if not exclusive me diators of the NPY -induced vascular responses in human brain vessels located both outside and within the cortical mantle. Interestingly, in endothelial cells from human umbilical vein, the YI receptor mRNA is only detectable during cell differentiation (Karwatoska-Prokopezuk et aI., 1996) . Therefore, although neither the NPY-Yl re ceptor's message nor protein were detected in any prepa ration of human brain endothelial cells, it cannot be ex cluded that these receptors can be induced during devel opment or by certain physiologic conditions.
In addition to being abundantly expressed in human brain cells, the current study shows that Y I receptors appear to be an integral and functional component of brain vascular and astroglial cells. This distribution con trasts with that of the other cloned NPY receptors, which were either never present (Y 4, Y5) or detected in only a few (Y2) cerebrovascular tissues or microvascular endo thelial cell cultures. The detection of a Y2 message in isolated microvascular fractions is likely attributable to the associated perivascular astrocytes (see later). The ap parent absence of endothelial NPY receptors is consis tent with previous studies in nonhuman vessels, both in peripheral arteries (Pernow and Lunberg, 1988) and mi crovessels (Kim et aI., 1994) . However, it cannot be excluded that Y2 receptors could regulate vascular func tions through receptors located presynaptically on nerve terminals, as documented in the peripheral circulation (Hashim and Tadepalli, 1995) or, alternatively, on as troglial cells, a cell type that is intimately associated with the microvascular bed.
We observed expression of multiple SUbtypes of NPY receptors (i.e., Yl, Y2, and Y4 receptors) in fetal human brain astrocytes. The presence of astroglial NPY recep tors had been reported previously in the rat, either by identification of specific binding sites for NPY in cul tures of rat brain astrocytes or by the observation of a membrane potential depolarization and an increase in [Ca 2 +]i after application of NPY (Hosli and Hosli, 1993; Gimpl et aI., 1993) . The possibility that these receptors are still expressed and functional in adult human brain deserves further investigation. Since astroglial cells are an integral component of isolated MV and CAP, the relative or complete absence of PCR products for the Y2 or Y 4 receptor in adult human isolated MV and CAP suggests that these receptors are expressed at low levels in adult astrocytes or, alternatively, that their primary location is not the perivascular astrocytes.
In conclusion, the current study demonstrates the ex-istence of Yl receptors not only on smooth muscle of human cerebral arteries, but also of intracortical mi crovessels. In view of the potent effect of NPY on nor mal brain perfusion and the documented increase in brain NPY levels or expression in focal ischemia (Cheung et aI., 1995) , the exclusive presence of NPY-Yl receptor on human brain myocytes may offer a unique opportunity to target the cerebrovascular system. Moreover, these data underscore the possibility that NPY released from human brain neurons can, through vascular smooth muscle Yl receptors, directly influence cerebrovascular functions related to regulation of local cerebral perfusion. They also suggest that NPY interactions could occur through astroglial receptors, which may be involved not only in the control of microvascular functions, but also of brain metabolic and ionic homeostasis, gliosis, and recovery after injury (Zoli et aI., 1997) .
